Skip header and navigation

2 records – page 1 of 1.

Document Type
Table
Review Code
INF220501 RR Table
Question Submitted
May 16, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
Infectious Disease
Document Type
Table
Review Code
INF220501 RR Table
Question Submitted
May 16, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
Infectious Disease
Category
Clinical Presentation
Diagnostics
Subject
Immunity
Infection Prevention and Control
Vaccination
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 4 Three weeks (21 days)
Cite As
Groot, G; Reeder, B; Muhajarine, N; Lee, S; Badea, A; Fox, L; Miller, L. What is known about hybrid immunity to COVID-19? 2022 Jun 06, Document no.: INF220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

INF220501 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
INF220501 RR
Question Submitted
May 16, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
Infectious Disease
Document Type
Rapid Review
Review Code
INF220501 RR
Question Submitted
May 16, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
Infectious Disease
Key Findings
There is substantial immunologic and increasing epidemiologic evidence that vaccination following infection further increases protection against subsequent illness among those who have been previously infected.
Laboratory studies indicate that hybrid immunity (i.e., immunity conferred by the combination of previous infection and vaccination) offers greater protection against COVID-19 infection.
A single dose of the AstraZeneca COVID-19 vaccine following SARS-CoV-2 infection induced a 2 to 3-fold increase in anti-Spike and -RBD IgG levels 30 days post-vaccination.
A study in Brazil found that hybrid immunity showed a modest increase in protection against symptomatic infection and waning over time.
Neutralising antibody titres against SARS-CoV-2 variants over 7 months following Pfizer vaccination in SARS-CoV-2-recovered and naïve healthcare workers resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against SARS-CoV-2 variants in recovered participants.
Pfizer and Moderna vaccines were associated with greater IgG responses compared to Johnson & Johnson regardless of administration following infection.
Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone.
A study on healthcare workers from Oregon Health & Science University found enhanced immune responses after vaccination in COVID-19 recovered (hybrid immunity) compared with their naïve-vaccinated peers. However, the effects of post-vaccination breakthrough infections on humoral immune response remain to be determined.
Category
Clinical Presentation
Diagnostics
Subject
Immunity
Infection Prevention and Control
Vaccination
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 4 Three weeks (21 days)
Cite As
Groot, G; Reeder, B; Muhajarine, N; Lee, S; Badea, A; Jagwani, M; Fox, L; Miller, L. What is known about hybrid immunity to COVID-19? 2022 Jun 06, Document no.: INF220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report).
Related Documents
Documents
Less detail